Eledon Pharmaceuticals, Inc. Payments to Acquire Debt Securities, Available-for-sale
Eledon Pharmaceuticals, Inc. (ELDN) reported Payments to Acquire Debt Securities, Available-for-sale of $59.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $16.26M, a 40.65% decline year-over-year.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $43.12M, a 35.39% increase year-over-year.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $69.22M, a 4.89% decline year-over-year.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $32.66M, a 4.29% decline year-over-year.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $161.13M, a 3.20% increase from fiscal 2024.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $156.13M, a 99.43% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $78.29M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $59.38M 10-Q · filed 2026-08-13 | $128.61M derived: sum of 3 quarters · filed 2026-08-13 | $161.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $43.12M 10-Q · filed 2026-05-13 | $112.34M derived: sum of 2 quarters · filed 2026-05-13 | $145.00M derived: sum of 3 quarters · filed 2026-05-13 | $172.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $69.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $101.88M derived: sum of 2 quarters · filed 2026-03-19 | $129.28M derived: sum of 3 quarters · filed 2026-08-13 | $161.13M 10-K · filed 2026-03-19 |
| 2025-09-30 | $32.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $60.06M derived: sum of 2 quarters · filed 2026-08-13 | $91.91M 10-Q · filed 2025-11-14 | $164.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $27.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $59.25M 10-Q · filed 2026-08-13 | $132.03M derived: sum of 3 quarters · filed 2026-08-13 | $166.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $31.85M 10-Q · filed 2026-05-13 | $104.63M derived: sum of 2 quarters · filed 2026-05-13 | $138.75M derived: sum of 3 quarters · filed 2026-05-13 | $175.06M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $72.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $106.90M derived: sum of 2 quarters · filed 2026-03-19 | $143.21M derived: sum of 3 quarters · filed 2026-03-19 | $156.13M 10-K · filed 2026-03-19 |
| 2024-09-30 | $34.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $70.43M derived: sum of 2 quarters · filed 2025-11-14 | $83.35M 10-Q · filed 2025-11-14 | $101.27M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $36.31M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-14 | $49.23M 10-Q · filed 2025-08-14 | $67.15M derived: sum of 3 quarters · filed 2025-08-14 | $97.18M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $12.92M 10-Q/A · filed 2025-08-14 | $30.84M derived: sum of 2 quarters · filed 2025-08-14 | $60.87M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2023-12-31 | $17.92M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-08-14 | $47.95M derived: sum of 2 quarters · filed 2025-08-14 | $78.29M 10-K/A · filed 2025-08-14 | |
| 2023-09-30 | $30.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $60.36M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $30.33M 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |